Digest Network Come funziona
Network
/
Società
Te
Non verificato

Teva Pharmaceutical Industries Ltd

Di cosa scriviamo

Annunci EconomiciFarmaceuticaFinanzaManagement/Organizzazione AziendaleMedicina Salute Benessere

113 comunicati stampa

Guarda tutti i comunicati
09/07/2026
Farmaceutica
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
07/07/2026
Farmaceutica
Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
18/06/2026
Farmaceutica
Annunci Economici
Teva Releases Q2 2026 Aide Memoire
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
18/06/2026
Farmaceutica
Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
18/06/2026
Farmaceutica
Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
10/06/2026
Farmaceutica
Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy 
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
08/06/2026
Farmaceutica
Medicina Salute Benessere
Teva’s Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
05/06/2026
Farmaceutica
Medicina Salute Benessere
Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
04/06/2026
Farmaceutica
Medicina Salute Benessere
Annunci Economici
Teva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
01/06/2026
Farmaceutica
Teva to Present at the Goldman Sachs Global Healthcare Conference
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0